Last month we wrote about Turing Pharmaceuticals, and the outrageous price increase they took on a life-saving drug called Daraprim. Remember that story? Turing Pharma bought the rights to sell Daraprim, and subsequently rose the price of the (generic) drug 5,000%.
Keep in mind this is a 62 year old drug that only cost patients $1 a pill a few years ago. The New York Times reports that “The Infectious Diseases Society of America and the HIV Medicine Association sent a joint letter to Turing earlier this month calling the price increase for Daraprim unjustifiable for the medically vulnerable patient population and unsustainable for the health care system,” a claim that Turing’s CEO denies. – The Senior List, 9/21/2015
Imprimis Offers Lower Prices on Expensive Drugs
There’s good news on this front. Imprimis Pharmaceuticals recently announced it will be selling it’s version of the specialty drug Daraprim. Their version will sell for $1 per pill versus the $750 that Turing Pharma is charging. When asked by CNN’s Kyung Lah, Imprimis CEO John Sharek said “There’s probably a point of inflection where if we try to push the limits and collect a little bit more money, we’re going to go against everything we’ve stood for as an organization.”
Does greed have to be the rule when it comes to pharmaceuticals in America? Absolutely not. – CNN’s Kyung Lah to Imprimis CEO John Sharek
At a time when big pharma is under the microscope, it’s good to know there’s a few companies (like Imprimis) looking out for the patient.